Sponsor content
216 result(s) found, displaying 11 to 20
-
Prescription medicine decision summaryAdzynma (apadamtase alfa/ cinaxadamtase alfa) has been approved for the treatment of ADAMTS13 deficiency in adults and children with congenital thrombotic thrombocytopenic purpura (cTTP).
-
Prescription medicine registrationActive ingredients: apadamtase alfa, cinaxadamtase alfa.
-
Prescription medicine registrationActive ingredients: Brentuximab vedotin.
-
Prescription medicine registrationActive ingredients: normal immunoglobulin.
-
Australian Public Assessment Report (AusPAR)Fruzaqla (fruquintinib) is approved for the treatment of adult patients with metastatic colorectal cancer (mCRC).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FRUZAQLA fruquintinib 1 mg hard capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FRUZAQLA fruquintinib 5 mg hard capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Syringe, general-purpose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TAKHZYRO lanadelumab 150 mg/1 mL solution for injection pre-filled syringe.
-
Prescription medicine registrationActive ingredients: fruquintinib.